|Calculated MW||32177 Da|
|Other Names||Cyclin-dependent kinase inhibitor 1C, Cyclin-dependent kinase inhibitor p57, p57Kip2, CDKN1C, KIP2|
|Target/Specificity||A synthetic peptide corresponding to residue within the internal region of human p57/KIP2 was used as an immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||p57/KIP2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Potent tight-binding inhibitor of several G1 cyclin/CDK complexes (cyclin E-CDK2, cyclin D2-CDK4, and cyclin A-CDK2) and, to lesser extent, of the mitotic cyclin B-CDC2. Negative regulator of cell proliferation. May play a role in maintenance of the non- proliferative state throughout life.|
|Tissue Location||Expressed in the heart, brain, lung, skeletal muscle, kidney, pancreas and testis. Expressed in the eye. High levels are seen in the placenta while low levels are seen in the liver.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
p57/KIP2 is a potent, tight-binding inhibitor of several G1 cyclin/Cdk complexes, and its binding is cyclin dependent. Its over-expression leads to arrest of the cell in G1 phase. Human p57/KIP2 appears to have conserved the amino- and carboxy-terminal domains but has replaced the internal regions with sequences containing proline-alanine repeats. Expression patterns suggest a complex role for p57/KIP2 cell cycle control and development (1). The gene encoding p57/KIP2 is located at a region implicated in both sporadic cancers and Beckwith-Wiedemann syndrome (BWS). Nonsense mutation found in the Cdk inhibitory domain in a BWS patient rendered p57/KIP2 inactive with consequent complete loss of its role as a cell cycle inhibitor and of its nuclear localization. Additionally, the mutation in the QT domain, although completely retaining its cell cycle regulatory activity, lacked nuclear localization and was thus prevented from performing its role as an active cell cycle inhibitor. (2). Mice lacking the imprinted Cdk inhibitor p57/KIP2 have altered cell proliferation and differentiation, leading to abdominal muscle defects; cleft palate; endochondral bone ossification defects with incomplete differentiation of hypertrophic chondrocytes (3).
1. Matsuoka S, et al. Genes Dev 9(6):650-62, 1995 2. Bhuiyan ZA, et al. Hum Genet 104(3):205-10, 1999 3. Zhang P et al. Nature 387(6629):151-8, 1997
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.